Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | THPO | P40225 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cystamine SCHEMBL3648870 | 0.74 | TSHR (1.00) | TSHRTHPOMAPTEHMT2TDP1 | |
| Cystamine SCHEMBL11040994 | 0.74 | — | — | |
| Cystamine SCHEMBL43866 | 0.74 | — | — | |
| SCHEMBL18210498 | 0.72 | TSHR (0.56) | TSHRTHPOMAPTEHMT2TDP1 | |
| SCHEMBL14516806 | 0.72 | TSHR (0.56) | TSHRTHPOMAPTEHMT2TDP1 | |
| Cystamine SCHEMBL28597938 | 0.72 | TSHR (0.77) | TSHRTHPOMAPTEHMT2TDP1 | |
| Cystamine SCHEMBL9193499 | 0.71 | — | — | |
| Cystamine SCHEMBL320311 | 0.71 | MAPT (1.00) | TSHRTHPOMAPTEHMT2TDP1 | |
| Cystamine SCHEMBL196510 | 0.71 | — | — | |
| Cystamine SCHEMBL31402311 | 0.71 | TSHR (0.91) | TSHRTHPOMAPTEHMT2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109069656-B | Oral nanoparticles for gene delivery and pharmaceutical compositions comprising the same | KB生物医药株式会社 | 2022-09-09 | — | — | CN | disclosed |
| EP-2285772-B1 | NEW CLASS OF CATIONIC LIPIDS FOR TRANSPORTING ACTIVE AGENTS INTO CELLS | OZ BIOSCIENCES SAS (FR) | 2022-07-13 | — | — | EP | disclosed |
| US-11266747-B2 | Orally administered nanoparticles for gene delivery and pharmaceutical composition containing same | KB BIOMED INC. (KR) | 2022-03-08 | — | — | US | disclosed |
| US-20190111156-A1 | Orally Administered Nanoparticles for Gene Delivery and Pharmaceutical Composition Containing Same | KB BIOMED INC. (KR) | 2019-04-18 | — | — | US | disclosed |
| CN-109069656-A | Oral nanoparticles for gene delivery and pharmaceutical compositions comprising the same | KB生物医药株式会社 | 2018-12-21 | — | — | CN | disclosed |
| EP-3017307-B1 | 3-ARYL PROPIOLONITRILE COMPOUNDS FOR THIOL LABELING | UNIV STRASBOURG (FR) | 2018-11-21 | — | — | EP | disclosed |
| US-10131626-B2 | 3-aryl propiolonitrile compounds for thiol labeling | UNIVERSITE DE STRASBOURG (FR) | 2018-11-20 | — | — | US | disclosed |
| US-20170210700-A1 | 3-ARYL PROPIOLONITRILE COMPOUNDS FOR THIOL LABELING | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2017-07-27 | — | — | US | disclosed |
| US-9663454-B2 | 3-aryl propiolonitrile compounds for thiol labeling | UNIVERSITE DE STRASBOURG (FR) | 2017-05-30 | — | — | US | disclosed |
| US-20160145199-A1 | 3-ARYL PROPIOLONITRILE COMPOUNDS FOR THIOL LABELING | UNIVERSITE DE STRASBOURG (FR) | 2016-05-26 | — | — | US | disclosed |
| US-7745590-B1 | Degradable macromolecular magnetic resonance imaging contrast agents and methods thereof | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2010-06-29 | — | — | US | disclosed |
| US-6982324-B1 | Degradable macromolecular magnetic resonance imaging contrast agents and methods thereof | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2006-01-03 | — | — | US | disclosed |
| EP-0650485-B1 | 2,5-DIARYL TETRAHYDRO-THIOPHENES, -FURANS AND ANALOGS FOR THE TREATMENT OF INFLAMMATORY AND IMMUNE DISORDERS | CYTOMED INC (US) | 2000-10-11 | — | — | EP | disclosed |
| US-5856323-A | PAF RECEPTOR ANTAGONISTS, INHIBITING THE ENZYME 5-LIPOXYGENASE | CYTOMED, INC. (US) | 1999-01-05 | — | — | US | disclosed |
| US-5434151-A | Treatment of immune and inflammatory disorders, aryl substituted tetrahydrofurans, tetrahydrothiophenes, cyclopentanes, pyrrolidines | CYTOMED, INC. (US) | 1995-07-18 | — | — | US | disclosed |
| EP-0650485-A1 | 2,5-DIARYL TETRAHYDRO-THIOPHENES, -FURANS AND ANALOGS FOR THE TREATMENT OF INFLAMMATORY AND IMMUNE DISORDERS | CYTOMED, INC. (US) | 1995-05-03 | — | — | EP | disclosed |
| US-5358938-A | 2,5-Diaryl tetrahydrofurans, tetrahydrothiophenes, 1,3-cyclo-pentanes and pyrrolidines | CYTOMED, INC. (US) | 1994-10-25 | — | — | US | disclosed |
| WO-1994001430-A1 | 2,5-DIARYL TETRAHYDRO-THIOPHENES, -FURANS AND ANALOGS FOR THE TREATMENT OF INFLAMMATORY AND IMMUNE DISORDERS | CYTOMED, INC. (US) | 1994-01-20 | — | — | WO | disclosed |
| US-4837316-A | ANTIULCER AGENTS | FUJIREBIO KABUSHIKI KAISHA (JP) | 1989-06-06 | — | — | US | disclosed |
| EP-0214823-A2 | Alkylamide derivatives with H2-receptor antagonistic and cytoprotective action | FUJIREBIO KABUSHIKI KAISHA also trading as FUJIREBIO INC. (JP) | 1987-03-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10131626-B2 | 3-aryl propiolonitrile compounds for thiol labeling | PTMS, TST, PNN | TSHR 2315/4885THPO 2814/4885MAPT 885/4885 |
| US-20170210700-A1 | 3-ARYL PROPIOLONITRILE COMPOUNDS FOR THIOL LABELING | PTMS, TST, PNN | TSHR 2315/4885THPO 2814/4885MAPT 885/4885 |
| US-20160145199-A1 | 3-ARYL PROPIOLONITRILE COMPOUNDS FOR THIOL LABELING | PTMS, TST, PNN | TSHR 2315/4885THPO 2814/4885MAPT 885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.